ENTITY
Lupin

Lupin (LPC IN)

279
Analysis
Health Care • India
Lupin is an Indian multinational pharmaceutical company that develops, manufactures, and markets a diverse range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company specializes in therapeutic areas such as cardiovascular, anti-diabetic, respiratory, anti-infective, and women's health. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
more
•20 Sep 2018 21:49

Global Equity Strategy: Opportunities in Japan and India

Our outlook for ex-U.S. markets (MSCI ACWI ex-U.S. index, local currency) remains neutral - bordering on cautious. Our concern stems from the...

Logo
635 Views
Share
bullish•Zensho Holdings
•19 Sep 2018 14:40

BBSP ASIA Equity Asia Weekly Research - 19 Sep 2018

THE MAIN IDEA(Relative Value Approach in USD Terms)Long Term Allocation (Strategic view) Relative Value vs MXAP in USD terms⦁ NIKKEI/MXAP: Long...

Logo
462 Views
Share
•10 Sep 2018 19:16

Para IV Winners and Losers - August 2018

This month’s Para IV developments suggest that there is likely to be benefit to Mylan Nv (MYL US) for Minivelle, Teva Pharmaceutical Sp Adr (TEVA...

Logo
417 Views
Share
•06 Aug 2018 17:11

Para IV Winners and Losers - July 2018

This month’s Para IV developments suggest that there is likely to be benefit to Par Pharma, Dr. Reddy'S Laboratories (DRRD IN) & Amneal...

Logo
470 Views
Share
•10 Jul 2018 15:02

Para IV Winners and Losers - June 2018

This month’s Para IV developments suggest that there is likely to be benefit to Baxter International Inc (BAX US) on Premix Precedex (4mc/ml), Endo...

Logo
510 Views
Share
x